Quarterly ResultMay 7, 2026, 04:28 PM
Enliven Therapeutics Q1 Net Loss Narrows to $23.6M; Cash $132.2M
AI Summary
Enliven Therapeutics reported a net loss of $23.6 million for the first quarter of 2026, an improvement compared to a $28.5 million net loss in the prior year period. The company ended the quarter with $132.2 million in cash and cash equivalents and $320.2 million in marketable securities. Enliven expects its current cash and investments to fund operating expenses and capital requirements for at least the next 12 months.
Key Highlights
- Net loss for Q1 2026 was $23.6 million, an improvement from $28.5 million in Q1 2025.
- Net loss per share improved to $(0.38) in Q1 2026 from $(0.57) in Q1 2025.
- Cash and cash equivalents increased to $132.2 million as of March 31, 2026, from $98.9 million at December 31, 2025.
- Marketable securities totaled $320.2 million as of March 31, 2026.
- Research and development expenses decreased to $20.7 million in Q1 2026 from $24.9 million in Q1 2025.
- Net cash used in operating activities decreased to $19.3 million in Q1 2026 from $24.1 million in Q1 2025.
- The company expects its $452.4 million in cash, cash equivalents, and marketable securities to fund operations for at least 12 months.
Price Impact
More from ELVN
Investment1d ago, 5:01 PM
Enliven Therapeutics Prices Upsized Public Offering for $400M Gross
Clinical Trial2d ago, 8:11 AM
Enliven Therapeutics Reports Positive Phase 1 Data for ELVN-001; FDA Aligns on Phase 3 Dose
Corporate Action3d ago, 6:01 AM
Enliven Therapeutics Increases Authorized Common Stock to 200M